Sanofi Company Profile (NYSE:SNY)

About Sanofi (NYSE:SNY)

Sanofi logoSanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company's segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NYSE:SNY
  • CUSIP: N/A
  • Web:
  • Market Cap: $125.63 billion
  • Outstanding Shares: 2,511,508,000
Average Prices:
  • 50 Day Moving Avg: $49.46
  • 200 Day Moving Avg: $48.26
  • 52 Week Range: $36.81 - $50.65
  • Trailing P/E Ratio: 11.50
  • Foreward P/E Ratio: 14.41
  • P/E Growth: 1.94
Sales & Book Value:
  • Annual Revenue: $43.62 billion
  • Price / Sales: 2.88
  • Book Value: $27.57 per share
  • Price / Book: 1.81
  • Annual Dividend: $1.10
  • Dividend Yield: 3.3%
  • EBITDA: $13.09 billion
  • Net Margins: 25.89%
  • Return on Equity: 25.34%
  • Return on Assets: 14.17%
  • Debt-to-Equity Ratio: 0.26%
  • Current Ratio: 1.59%
  • Quick Ratio: 1.16%
  • Average Volume: 1.11 million shs.
  • Beta: 0.87
  • Short Ratio: 1.35

Frequently Asked Questions for Sanofi (NYSE:SNY)

What is Sanofi's stock symbol?

Sanofi trades on the New York Stock Exchange (NYSE) under the ticker symbol "SNY."

How often does Sanofi pay dividends? What is the dividend yield for Sanofi?

Sanofi announced an annual dividend on Friday, February 17th. Investors of record on Monday, May 15th will be paid a dividend of $1.5771 per share on Wednesday, June 7th. This represents a yield of 3.65%. The ex-dividend date of this dividend is Thursday, May 11th. This is a positive change from Sanofi's previous annual dividend of $1.10. View Sanofi's Dividend History.

How were Sanofi's earnings last quarter?

Sanofi (NYSE:SNY) posted its quarterly earnings data on Monday, July, 31st. The company reported $0.74 earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of $0.74. The business earned $8.66 billion during the quarter, compared to analysts' expectations of $8.71 billion. Sanofi had a net margin of 25.89% and a return on equity of 25.34%. The firm's quarterly revenue was down 2.3% on a year-over-year basis. View Sanofi's Earnings History.

When will Sanofi make its next earnings announcement?

Sanofi is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for Sanofi.

Where is Sanofi's stock going? Where will Sanofi's stock price be in 2017?

11 brokers have issued 1 year price targets for Sanofi's stock. Their predictions range from $52.00 to $55.00. On average, they expect Sanofi's share price to reach $53.50 in the next twelve months. View Analyst Ratings for Sanofi.

What are analysts saying about Sanofi stock?

Here are some recent quotes from research analysts about Sanofi stock:

  • 1. According to Zacks Investment Research, "Sanofi’s Diabetes franchise is under significant pressure with key product, Lantus facing increasing competitive pressure at the payor level and the presence of biosimilar competition in several European markets and Japan. Sanofi’s outlook for its Diabetes franchise is also bleak due to a tough U.S. payer environment. At the Q2 conference call, management warned that US diabetes sales will decline faster in the second half. Other headwinds include generic competition and slower-than-expected uptake of new products like Praluent. Sanofi’s shares have underperformed the industry in the past three months. However, Sanofi's focus on streamlining its business and pursuing business development deals is encouraging. Further, new drugs like Aubagio and Lemtrada are likely to continue doing well. Estimates have remained stable ahead of Q3 earnings release. Sanofi has a positive record of earnings surprises in recent quarters." (10/6/2017)
  • 2. Argus analysts commented, "The company also has a strong new drug pipeline that includes Toujeo, a next-generation insulin product, and dipilumab, for atopic dermatitis and other inflammatory conditions," the analyst said.See also: Where Does Zika Virus Vaccine Research Stand Now? FY18 ExpectationsArgus expects the company's 2017 revenues from continuing operations to benefit from the recent acquisition of Boehringer Ingelheim's consumer health business and higher sales of multiple sclerosis products. At the same time, the firm expects reduced diabetes drug sales.The firm also sees margin pressure due to pricing pressures for diabetes products in the U.S. and costs related to the launch of Dupixent and Kevzara, partly offset by a sales force reorganization and other cost-savings initiatives."In 2018, we expect continued solid demand for multiple sclerosis drugs and increased sales in emerging markets to outweigh weaker sales of diabetes drugs, and look for the company's cost-savings program to benefit margins," (9/1/2017)

Who are some of Sanofi's key competitors?

Who are Sanofi's key executives?

Sanofi's management team includes the folowing people:

  • Serge Weinberg, Independent Chairman of the Board
  • Olivier Brandicourt, Chairman of the Executive Committee, Chief Executive Officer, Director
  • Jerome Contamine, Executive Vice President, Chief Financial Officer, Member of the Executive Committee
  • Karen Marie Linehan, Executive Vice President, Legal Affairs and General Counsel; Member of the Executive Committee
  • Olivier Charmeil, Executive Vice President and General Manager, General Medicines & Emerging Markets; Member of the Executive Committee
  • Roberto Pucci, Executive Vice President, Human Resources; Member of the Executive Committee
  • Peter Guenter, Executive Vice President, Diabetes & Cardiovascular; Member of the Executive Committee
  • David Loew, Executive Vice President, Sanofi Pasteur; Member of the Executive Committee
  • Philippe Luscan, Executive Vice President, Global Industrial Affairs; Member of the Executive Committee
  • Alan J. Main Ph.D., Executive Vice President, Consumer Healthcare; Member of the Executive Committee

Who owns Sanofi stock?

Sanofi's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Beacon Financial Group (0.00%), Fulton Bank N.A. (0.00%) and Eqis Capital Management Inc. (0.00%). View Institutional Ownership Trends for Sanofi.

Who sold Sanofi stock? Who is selling Sanofi stock?

Sanofi's stock was sold by a variety of institutional investors in the last quarter, including Fulton Bank N.A.. View Insider Buying and Selling for Sanofi.

Who bought Sanofi stock? Who is buying Sanofi stock?

Sanofi's stock was purchased by a variety of institutional investors in the last quarter, including Beacon Financial Group and Eqis Capital Management Inc.. View Insider Buying and Selling for Sanofi.

How do I buy Sanofi stock?

Shares of Sanofi can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sanofi's stock price today?

One share of Sanofi stock can currently be purchased for approximately $50.02.

MarketBeat Community Rating for Sanofi (NYSE SNY)
Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  234 (Vote Outperform)
Underperform Votes:  290 (Vote Underperform)
Total Votes:  524
MarketBeat's community ratings are surveys of what our community members think about Sanofi and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Sanofi (NYSE:SNY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 6 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.27)
Consensus Price Target: $53.50 (6.96% upside)
Consensus Price Target History for Sanofi (NYSE:SNY)
Price Target History for Sanofi (NYSE:SNY)
Analysts' Ratings History for Sanofi (NYSE:SNY)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/15/2017J P Morgan Chase & CoReiterated RatingNeutralLowView Rating Details
9/1/2017ArgusReiterated RatingBuy$55.00MediumView Rating Details
8/30/2017HSBC Holdings plcUpgradeReduce -> HoldMediumView Rating Details
8/1/2017Cowen and CompanyReiterated RatingMarket Perform$46.00 -> $52.00LowView Rating Details
5/11/2017Berenberg BankDowngradeBuy -> HoldLowView Rating Details
3/9/2017Liberum CapitalInitiated CoverageHold -> HoldLowView Rating Details
3/7/2017Barclays PLCInitiated CoverageUnderweightN/AView Rating Details
2/9/2017NatixisUpgradeNeutral -> BuyN/AView Rating Details
1/10/2017Leerink SwannReiterated RatingOutperformN/AView Rating Details
1/8/2017Goldman Sachs Group, Inc. (The)Reiterated RatingHoldN/AView Rating Details
11/29/2016Morgan StanleyUpgradeEqual Weight -> OverweightN/AView Rating Details
9/23/2016Piper Jaffray CompaniesInitiated CoverageNeutralN/AView Rating Details
9/14/2016Jefferies Group LLCReiterated RatingHoldN/AView Rating Details
9/13/2016BNP ParibasUpgradeUnderperform -> NeutralN/AView Rating Details
6/28/2016Citigroup Inc.Reiterated RatingNeutralN/AView Rating Details
5/3/2016Bank of America CorporationReiterated RatingBuy$58.00N/AView Rating Details
4/12/2016Chardan CapitalReiterated RatingBuyN/AView Rating Details
2/10/2016Sanford C. BernsteinLower Price TargetMarket-Perform$52.00 -> $45.00N/AView Rating Details
12/16/2015Oddo SecuritiesDowngradeReduceN/AView Rating Details
11/9/2015Bryan, Garnier & CoReiterated RatingBuy -> NeutralN/AView Rating Details
(Data available from 10/19/2015 forward)


Earnings History for Sanofi (NYSE:SNY)
Earnings by Quarter for Sanofi (NYSE:SNY)
Earnings History by Quarter for Sanofi (NYSE SNY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017$0.96N/AView Earnings Details
7/31/20176/30/2017$0.74$0.74$8.71 billion$8.66 billionViewN/AView Earnings Details
4/28/20173/31/2017$0.73$0.76$8.40 billion$8.65 billionViewN/AView Earnings Details
2/8/2017Q416$0.66$0.67$9.87 billion$8.88 billionViewN/AView Earnings Details
10/29/2015Q315$0.88$0.89$10.97 billion$10.67 billionViewN/AView Earnings Details
4/30/2015Q115$0.61$0.73$9.21 billion$9.78 billionViewN/AView Earnings Details
2/5/2015Q4$0.89$0.79$11.34 billion$10.39 billionViewN/AView Earnings Details
7/31/2014Q2$0.79$0.72$11.19 billion$10.82 billionViewN/AView Earnings Details
4/29/2014Q114$0.84$0.81$11.19 billion$10.88 billionViewN/AView Earnings Details
2/6/2014Q4$0.88$0.93ViewN/AView Earnings Details
10/30/2013$1.01$0.93ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Sanofi (NYSE:SNY)
2017 EPS Consensus Estimate: $3.21
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.75$0.78$0.77
Q2 20171$0.74$0.74$0.74
Q3 20171$0.90$0.90$0.90
Q4 20171$0.80$0.80$0.80
(Data provided by Zacks Investment Research)


Current Dividend Information for Sanofi (NYSE:SNY)
Most Recent Dividend:6/7/2017
Annual Dividend:$1.10
Dividend Yield:2.20%
Dividend Growth:-2.50% (3 Year Average)
Payout Ratio:28.06% (Trailing 12 Months of Earnings)
33.13% (Based on This Year's Estimates)
31.70% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Sanofi (NYSE:SNY)

Dividend History by Quarter for Sanofi (NYSE SNY)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Sanofi (NYSE:SNY)
Insider Ownership Percentage: 1.00%
Institutional Ownership Percentage: 9.33%
Insider Trades by Quarter for Sanofi (NYSE:SNY)
Institutional Ownership by Quarter for Sanofi (NYSE:SNY)
Insider Trades by Quarter for Sanofi (NYSE:SNY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/24/2017SanofiMajor ShareholderBuy105,820$482.04$51,009,472.80View SEC Filing  
8/23/2017SanofiMajor ShareholderBuy60,595$478.98$29,023,793.10View SEC Filing  
7/9/2014SanofiMajor ShareholderBuy195,000$308.27$60,112,650.00View SEC Filing  
7/8/2014SanofiMajor ShareholderBuy153,000$311.67$47,685,510.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Sanofi (NYSE:SNY)
Latest Headlines for Sanofi (NYSE:SNY)
DateHeadline logoA scientific breakthrough offers hope for an AIDS vaccine - October 19 at 9:55 AM logoSanofi/Regeneron's Dupixent Succeeds in Phase II Study - October 18 at 8:45 AM logoSanofi (SNY), Regeneron (REGN) Phase 2 Study Results for Dupilumab Shows Significant Improvement Versus Placebo - October 18 at 8:45 AM logoSanofi’s Consumer Healthcare Expected to Be Long-Term Driver - October 18 at 8:45 AM logoSanofi and Regeneron Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis - October 17 at 7:26 AM logoRegeneron Pharma, Sanofi Announce Positive Phase 2 Study Results For Dupilumab - October 17 at 7:26 AM logoSanofi: Upward Trajectory In 2017 - October 17 at 7:26 AM logoDupixent May Be Strong Growth Driver for Sanofi in the Future - October 17 at 7:26 AM logoRegeneron Advances Science To Attack Arthritis, Eye Disease, More - October 17 at 7:26 AM logoRegeneron and Sanofi Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis - October 17 at 7:26 AM logoRegeneron-Sanofi throat infection drug succeeds key study - October 17 at 7:26 AM logoSanofi’s Kevzara Could Be Solid Addition to Rheumatoid Arthritis - October 17 at 7:26 AM logoSanofi: Sanofi: Availability of the Pre-quarterly Results Communication - October 13 at 8:55 AM logoSanofi Invests €170 Mln In New Vaccine Production Facility In France - October 13 at 8:55 AM logoSanofi to invest €170M to expand France vaccine manufacturing site - October 13 at 8:55 AM logoSanofi invests €170 million in new vaccine production facility in France - October 12 at 1:58 AM logoCritical Review: Sanofi (SNY) and Its Peers - October 11 at 10:30 AM logo5 Pharma & Biotech Stocks That Could Be Big Winners in Q3 Earnings - October 10 at 1:19 PM logoEmergent BioSolutions Acquires Sanofi's Smallpox Vaccine Unit - Nasdaq - October 10 at 6:57 AM logoUPDATE: Sanofi (SNY), Regeneron (REGN) Win New Trial in Amgen (AMGN) Case over Praluent - Bloomberg - - October 7 at 8:41 AM logoSanofi & Regeneron win appeal of PCSK9 patent ruling versus Amgen - October 6 at 11:32 AM logoAppellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent® (alirocumab) - October 6 at 11:32 AM logoRegeneron and Sanofi Get Favorable Ruling Against Amgen - October 6 at 11:32 AM logoAnalytics Keep Sanofi (SNY) Strong Buy Ranking - October 6 at 10:37 AM logoSanofi (SNY) Cut to "Strong Sell" at Zacks Investment Research - October 6 at 9:36 AM logoSanofi ready to launch sale of European generic business; shares up 1% - October 5 at 7:40 PM logoCourt reverses ban on sales of Sanofi, Regeneron drug Praluent - October 5 at 10:43 AM logoSanofi (SNY) Receives Consensus Rating of "Hold" from Analysts - October 4 at 11:04 PM logoSanofi Appoints Stefan Oelrich Executive Vice President Diabetes & Cardiovascular - October 2 at 9:21 AM logoA Starting Point For Big Pharma: Do Novartis And Sanofi Clear The Hurdles? - October 2 at 9:21 AM logoSanofi: The Worst Isn't Behind - September 30 at 10:50 AM logoSanofi (SNY) & Regeneron (REGN) Report Approval of Dupixent (Dupilumab) in European Union to Treat Adult ... - - September 29 at 6:38 AM logoHead-To-Head Comparison: Apricus Biosciences (APRI) vs. Sanofi (SNY) - September 28 at 4:22 PM logoSanofi and Regeneron Announce Approval of Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union - September 28 at 2:44 AM logoSanofi and Regeneron Announce Approval of Dupixent® (dupilumab) to Treat Adult ... - September 28 at 2:29 AM logoSanofi, Regeneron: Dupixent Gets EU Approval To Treat Atopic Dermatitis - September 28 at 2:28 AM logoAlnylam And Sanofi Achieve An RNAi First - Seeking Alpha - September 27 at 4:26 PM logoPre-Market Most Active for Sep 27, 2017 : MU, BAC, TLT, ERIC, AAPL, CASC, GSK, CTLT, SNY, QQQ, NKE, TOT - Nasdaq - September 27 at 4:26 PM logoIs Sanofi (SNY) a Great Stock for Value Investors? - September 23 at 7:40 AM logoSanofi (SNY) Presents At Bank of America Merrill Lynch 2017 Global Healthcare Conference - Slideshow - September 19 at 7:55 AM logoAceto Corporation (ACET) and Sanofi (SNY) Head to Head Survey - September 18 at 6:40 PM logoSanofi: Sanofi and Regeneron Announce Positive Study Results for Dupixent® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis - September 17 at 8:03 AM logoJ P Morgan Chase & Co Reaffirms Neutral Rating for Sanofi SA (SNY) - September 15 at 2:34 PM logoSanofi Reports Results Of TAKE CONTROL Study - Quick Facts - Nasdaq - September 14 at 10:26 AM logoSanofi (SNY) Says New Post-hoc Analysis Shows Soliqua 100/33 Provided Earlier Blood Sugar Control than Insulin ... - - September 14 at 10:26 AM logoReviewing Sanofi (SNY) & Eyegate Pharmaceuticals (EYEG) - September 14 at 12:26 AM logoRegeneron/Sanofi's Dupixent Asthma Study Meets Endpoints - September 12 at 10:01 AM logoSanofi Reports Post-hoc Analysis Of Phase 3 Soliqua 100/33 Trials - September 12 at 10:01 AM logoFeatured Company News - Regeneron Pharma and Sanofi's Cemiplimab Receives Breakthrough Therapy Designation from US FDA - September 12 at 10:01 AM logoMinerva Neurosciences Names Dr. Jay Saoud as Senior Vice President, Head of Research and Development - September 11 at 9:23 AM



Sanofi (SNY) Chart for Thursday, October, 19, 2017

This page was last updated on 10/19/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.